FindTrial
Sign In

To Investigate whether resveratrol and copper can reduce the amount of virus load in patients with Chronic Hepatitis B and C virus infection

A prospective pilot study to assess the effect of Resveratrol-Copper on the viral load in patients with Chronic Hepatitis B and C virus infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/053055
Enrollment
20
Registered
2023-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B191- Unspecified viral hepatitis B

Interventions

Intervention1: Resveratrol and copper: Resveratrol and copper will be only for a period of 4 weeks given in a four times a day schedule for 28 days. The concentrations of Resveratrol 5.6 mg Copper 56

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Age above 18 years -ECOG- performance status of 0 or 1 -Chronic HBV infection with HBV DNA levels more than equal to 2000 IU per mL and normal ALT alanine amino transferase These patients are not routinely treated with antivirals due to limited activity. ALT is traditionally considered to be marker of hepatocellular injury. Various studies using interferon, peg interferon, Lamivudine, Adefovir have shown the importance of elevated ALT levels in predicting the response rate to therapy -Chronic HCV infection with detectable HCV RNA levels and Genotype 2 or -who are eligible for antiviral treatment as per standard guidelines -No active malignancy at least 1 year of DFS following successful anticancer Rx -Adequate hepatic, renal, and hematologic function at baseline -Patients who have given written informed consent

Exclusion criteria

Exclusion criteria: -Age more 60 years -Any other Genotype of HCV -Acute Hepatitis -Cirrhosis -Decompensated chronic liver disease -Concurrent chemotherapy -Current or previous antiviral treatment for HBV or HCV -Coexistent dual infection- i.e. HBV with HCV -Coexistent HIV infection -Uncontrolled medical comorbidities like hypertensive, diabetes mellitus -Patients taking alternative/ complementary treatments

Design outcomes

Primary

MeasureTime frame
To evaluate change in the viral load after oral administration of R-Cu in a four times daily dosing for 4 weeksTimepoint: 2 years—

Secondary

MeasureTime frame
To evaluate the safety of R-Cu in patients with chronic hepatitis B and CTimepoint: 2 years—

Countries

India

Contacts

Public ContactDr Prachi Patil

Tata Memorial Hospital

prachipatil@gmail.com022-24177205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026